Letters
Risks of non-oncology phase I research
Time to abandon three-phase trials?
BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i764 (Published 17 February 2016) Cite this as: BMJ 2016;352:i764
- Andrew V Metcalfe, associate professor in statistics1
- 1University of Adelaide, Adelaide, SA 5005, Australia
- andrew.metcalfe{at}adelaide.edu.au
Emmanuel and colleagues conclude that “concerns about the high risks of serious harm in non-oncology phase I trials do not seem to be borne out.”1 But, although the risk may be small, the consequences can be tragic.2 3
Nevertheless, randomised controlled trials (RCTs) are widely considered the gold standard for clinical research, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.